Puma Biotechnology, Inc. splits its revenue into 2 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Product at $53.6 million, 95% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
231
|
57
|
45
|
75
|
54
|
52
|
46
|
59
|
81
|
| Product |
207
+2.2%
share 89.6%
|
54
+8.9%
share 94.8%
|
42
-2.7%
share 93.6%
|
60
+10.1%
share 79.4%
|
52
-7.5%
share 95.3%
|
49
share 93.8%
|
43
share 93.7%
|
54
share 92.0%
|
56
share 69.7%
|
| Royalty |
24
-32.1%
share 10.4%
|
3
-9.4%
share 5.2%
|
3
-1.7%
share 6.4%
|
16
+231.3%
share 20.6%
|
3
-89.5%
share 4.7%
|
3
share 6.2%
|
3
share 6.3%
|
5
share 8.0%
|
24
share 30.3%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PBYI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Los Angeles, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1401667
- Former names
- INNOVATIVE ACQUISITIONS CORP (until Oct 4, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.